Precision Oncology Program (POP), an observational study using real-world data and imaging mass cytometry to explore...

Area of Science:

• Oncology
• Bioinformatics
• Proteomics

Background:

• Precision oncology requires robust evidence for individualized treatment recommendations.
• Increasing biomarkers and therapeutic targets create a need for integrated data approaches.
• The Precision Oncology Program (POP) addresses this by evaluating combined data modalities.

Purpose of the Study:

• To assess the feasibility and utility of integrating real-world data (RWD) and imaging mass cytometry (IMC) for personalized cancer treatment.
• To evaluate if patient-matched clinicogenomic data and spatial proteomics can inform treatment decisions at the Molecular Tumor Board.
• To leverage a nationwide de-identified clinicogenomic database for cohort matching and data analysis.

Main Methods:

• Recruitment of patients across all tumor types and stages at the Comprehensive Cancer Center Zurich.
• Identification of matched cohorts in the Flatiron Health-Foundation Medicine clinicogenomic database (CGDB).
• Performance of multiplexed imaging mass cytometry (IMC) on formalin-fixed paraffin-embedded tissues.
• Review of RWD and IMC data by the Molecular Tumor Board for potential impact on therapy decisions.

Main Results:

• The study is observational, and recommendations derived from RWD and IMC are non-prescriptive.
• The feasibility and utility of integrating clinicogenomic data and spatial proteomics are under evaluation.
• The potential impact of these integrated data modalities on personalized treatment decisions is being assessed.

Conclusions:

• The Precision Oncology Program demonstrates a novel approach to integrating diverse data sources for cancer treatment.
• This program aims to enhance profiling-driven decision-making in precision oncology.
• Findings will contribute to evidence generation for individualized cancer therapies.